

Drug Monograph

Drug/Drug **DermacinRx Purefolix™ (folic acid and vitamin d) tablet/**
 Class: **Multivitamin/Multimineral**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: DermacinRx Purefolix™ is available as a tablet containing 1 mg folic acid and 5000 IU cholecalciferol respectively.

Manufacturer: PureTek Corporation San Fernando, CA 91340

Indications: DermacinRx Purefolix™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation.

Costs: Pricing information not available.

Summary of Findings: The MO HealthNet Division recommends prior authorization status for this product.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Under Solicitation
 Appropriate Indications No PA Required

Prepared By: Luke Boehmer Pharm.D.
 Date: February 24, 2016